Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market Size to Grow by USD 1.79 billion, AbbVie Inc. and Bayer AG Among Key Vendors - Technavio

Source :: PR Newswire. July 25, 2022
Publication Year :: 2022
Abstract: NEW YORK, July 25, 2022 /PRNewswire/ -- DLBCL is a cancer of B-lymphocytes and is the most common type of Non-Hodgkins Lymphoma (NHL) among adults. It is a fast-growing and [...]

Subjects :: Merck & Company Inc. -- Forecasts and trends
Spectrum Pharmaceuticals Inc. -- Forecasts and trends
ADC Therapeutics S.A. -- Forecasts and trends
Amgen Inc. -- Forecasts and trends
Bayer AG -- Forecasts and trends
AbbVie Inc. -- Forecasts and trends
Pfizer Inc. -- Forecasts and trends
Novartis AG -- Forecasts and trends
Biotechnology industry -- Forecasts and trends
Non-Hodgkin's lymphomas -- Forecasts and trends -- Reports
Pharmaceutical industry -- Forecasts and trends
Market trend/market analysis
Business
News, opinion and commentary

Tools